Experimental cancer drug ART0380 trial halted early

NCT ID NCT05798611

Terminated Disease control Sponsor: Artios Pharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ART0380 (an ATR kinase inhibitor taken orally)
What this could lead to: If successful, ART0380 could offer a new treatment option for people with advanced solid tumors that have specific genetic features.
What could go wrong: This trial was terminated early, so results are limited. The drug is still experimental, and its safety and effectiveness are not yet proven. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC CANCER RECURRENT ENDOMETRIAL CANCER

Contacts and locations

Locations

Centre Francois Baclesse - Service d'Oncologie médicale

Caen, NAP, 14076, France
Centre Hospitalier Universitaire De Poitiers

Poitiers, NAP, 86000, France
Dana Farber Cancer Center

Boston, Massachusetts, 02215, United States
Fundación Instituto Valenciano De Oncología

Valencia, 46009, Spain
Hopital Cochin Saint Vincent De Paul

Paris, NAP, 75014, France
Hopital Lyon Sud

Pierre-Bénite, NAP, 69310, France
Hospital Universitario De Jaén

Jaén, Andalusia, 23007, Spain
Institut de Cancérologie de l'Ouest

Angers, NAP, 49055, France
Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology

New York, New York, 10065, United States
Northwell Health R.J. Zuckerberg Cancer Center

Lake Success, New York, 11042, United States
The University of Chicago

Chicago, Illinois, 60637-1447, United States
University of California Los Angeles (UCLA)

Los Angeles, California, 90095-1781, United States
University of Oklahoma/Sarah Cannon Research Institute

Oklahoma City, Oklahoma, 73104, United States
Western Pennsylvania Hospital

Pittsburgh, Pennsylvania, 15224, United States
Women and Infants Hospital

Providence, Rhode Island, 02905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.